Stiripentol increases plasma levels of clobazam and its active metabolite N-desmethylclobazam, through inhibition of CYP3A and CYP2C19.

Monitoring of blood levels is recommended, prior to initiation of stiripentol, and then once new steady-state concentration has been reached, i.e. after 2 weeks approximately.

Monitoring of blood levels is recommended, prior to initiation of stiripentol, and then oncenew steady-state concentration has been reached, i.e. after 2 weeks approximately.

Monitoring of blood levels is recommended, prior to initiation of stiripentol, and then once new steady-state concentration has been reached, i.e. after 2 weeks approximately.

We are continuing our research on stiripentol in order to do everything in our power to improve treatment for children and adults suffering from pharmacoresistant epilepsy.

Stiripentol should be started at a low dose and increased over 3 days to a daily dose of 50 mg per kilogram of body weight.

Additional adequately powered studies with long-term follow-up should be conducted to unequivocally establish the long-term efficacy and tolerability of STP in the treatment of patients with SMEI.

Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, refractory form of epilepsy, for which stiripentol (STP) has been recently licensed as add-on therapy.

Monitoring of blood levels is recommended, prior to initiation of stiripentol, and then oncenew steady-state concentration has been reached, i.e. after 2 weeks approximately.